02186.HK
Luye Pharma Group Ltd.
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 1.75
+2.94%Year over year
Reported trailing growth
- Revenue
- -1.3%
- EBITDA
- +27.5%
- EBIT
- +23.2%
- EPS
- +63.5%
- Free cash flow
- -62.9%
- Operating cash flow
- -85.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.8%
- EBITDA
- +3.6%
- EBIT
- +12.2%
- Net income
- +0.8%
- EPS
- -2.0%
- Free cash flow
- +16.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026